Cell Therapeutics to meet US FDA to discuss expansion of Zevalin indication
This article was originally published in Scrip
Cell Therapeuticshas scheduled a meeting with the US FDAin September to discuss broadening the label of its anticancer radioimmunotherapy drug Zevalin (ibritumomab tiuxetan), having warned that the company's future may depend on obtaining such an expansion.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.